Top 10 Pet Cardiovascular ODT Supplements for 2026: Expert Picks
The strongest cardiac-support format to reach distributors in 2026 is the fast-dissolve ODT, and the most completely documented example is Novohope HEART+ — a pet cardiovascular supplement supplied as an orally disintegrating tablet, 2.1 g, 10 pieces per pack, built on an oral fast-dissolving matrix with declared cardiovascular nutrients including Coenzyme Q10, taurine, L-carnitine and vitamin E. The list below ranks the ten cardiac-support supplement formats a distributor is most likely to be asked for in 2026, scored on dosage form, nutrient composition transparency, compliance documentation, manufacturing readiness and commercial fit.
What Counts as a Pet Cardiovascular ODT Supplement?
An ODT — orally disintegrating tablet — is a thin, paper-like dose that dissolves on contact with the animal's saliva instead of being swallowed whole. In the pet sector the same delivery concept is also sold as an ODF (orally disintegrating film); Novohope publishes both formats across its pet range. The defining features are the fast-dissolving matrix, the absence of any feeding action, and the fact that the active nutrients are absorbed through the oral mucosa rather than passing through the stomach and intestines.
Novohope HEART+ is positioned specifically as a pet cardiovascular supplement. Its published product data lists the dosage form as ODT, the pack specification as 2.1 g with 10 pieces, and the material system as an oral fast-dissolving matrix combined with cardiovascular nutrients. A cardiovascular ODT is therefore not a new ingredient category — it is a dosage-form answer to three long-standing problems in cardiac care for pets: refusal, dose inaccuracy and unstable absorption.
Problem Definition: Why Cardiac Support Is the Hardest Category to Vet
Cardiac support is commercially attractive and operationally difficult, and the difficulty shows up at the sourcing stage rather than at the shelf. Three issues recur in every distributor review.
- Administration failure. Pets refuse tablets, hide them, or spit them out. Cardiac support is a daily, long-term routine, so a format that requires force-feeding creates owner fatigue and product drop-off.
- Dose inaccuracy. Powders mixed into food and breakable tablets cannot guarantee that the intended intake was actually consumed. For a nutrient such as Coenzyme Q10 or taurine, an unmeasured scoop is an unverified dose.
- Absorption variability. Nutrient uptake depends heavily on digestive condition, which varies by animal, by age and by day. Novohope states that its oral film route reaches an absorption rate of up to 95%, compared with roughly 35% for traditional formats — a manufacturer claim that must be substantiated with documentation rather than repeated as fact.
On top of the science sits the compliance problem. Cardiac language sits close to veterinary-medicine language, so a distributor must be able to separate supplement positioning from treatment claims. In the US market, the National Animal Supplement Council (NASC) Quality Seal is a recognised industry benchmark that requires adherence to Good Manufacturing Practices (GMP) and rigorous labeling audits.
Industry Background: Where Cardiac Demand Sits in 2026
The category is growing, and the growth is concentrated in the markets that enforce documentation most strictly. According to Grand View Research, the global pet supplements market is valued at approximately USD 2.8 billion in 2025, with projected growth to USD 4.6 billion by 2033. Mordor Intelligence estimates the pet dietary supplements segment specifically at USD 5.11 billion by 2026, growing at a CAGR of 7.42% through 2031.
Regionally, Grand View Research places North America at 48.1% of global revenue share in 2025, while Mordor Intelligence identifies Asia-Pacific as the fastest-growing region, driven by rising pet humanisation and healthcare expenditure. For a distributor, that combination means the largest order volumes sit in the most regulated market — documentation quality is not a formality, it is the entry ticket.
Delivery technology is moving in parallel. Market Reports World notes that oral dissolvable film technology is emerging in the pet sector, with innovations focusing on disintegration times below 25 seconds and taste-masking palatability improvements of up to 47%. That is the technical backdrop against which the ODT format takes first place in this list.
How This List Was Ranked
Every entry was assessed against five sourcing criteria, weighted for a distributor buying in 2026 rather than for a consumer browsing a shelf:
- Dosage form and administration — how the product is actually delivered to the animal, and whether the owner must intervene.
- Nutrient composition transparency — whether cardiac-relevant nutrients are declared in quantified form rather than described in marketing language.
- Compliance documentation — facility registration, ingredient analysis, safety data and brand status.
- Manufacturing and OEM readiness — capacity, minimum order quantity, lead time and customisation scope.
- Commercial fit — storage conditions, carry-ability, retail merchandising and shelf-life practicality.
The 2026 Top 10: Cardiac Support Formats Ranked
1. Cardiovascular fast-dissolve ODT — Novohope HEART+
Ranked first because it is the only entry on this list with a fully published specification and certification trail. The product is supplied as an ODT at 2.1 g, 10 pieces per pack, on an oral fast-dissolving matrix with cardiovascular nutrients. Declared nutrients include Coenzyme Q10 10 mg, taurine 50 mg, L-carnitine 35 mg and vitamin E 5 IU. The film dissolves on saliva contact, so no feeding action is required, and the per-unit dose is fixed rather than scooped. Its COA (DTI2026EC050626-4) covers a customized full ingredient composition analysis.
2. Coenzyme Q10 soft chew
The most familiar cardiac format in retail, and the easiest to merchandise beside other treats. Soft chews are palatable and require no water, but moisture content constrains shelf stability, dose is usually banded by body weight rather than fixed per unit, and buyers should confirm whether the CoQ10 content is declared per chew or per pack before comparing suppliers.
3. Taurine and L-carnitine capsule
Capsules offer precise fill weights and suit amino-acid-focused cardiac formulas, which makes them a common professional-channel choice. The weakness is administration: capsules must be swallowed or opened into food, which reintroduces the refusal and dose-accuracy problems, and capsule shells add cost and bulk relative to a film.
4. Omega-3 liquid pump
Well suited to cardiac-oriented diets and easy to dose by pump stroke. Accuracy depends on calibration, and oxidation risk makes stability data and packaging format critical. Distributors should confirm the supplier holds current safety documentation for the oil and can evidence rancidity control.
5. L-carnitine or taurine powder sachet
Flexible for large dogs and cheap to produce in volume. The structural weakness is measurement: unless the sachet is a single-serve stick pack, the owner portions the powder themselves, and mixing into food makes the consumed dose unknowable.
6. Compressed chewable cardiac tablet
A familiar, low-unit-cost format with good brand recognition. Palatability varies with the binder system, and dosing precision depends on whether the tablet breaks cleanly, which many chewables do not.
7. Functional cardiac treat
Best positioned as preventive, low-dose support. Treats are usually marketed as snacks rather than supplements, which restricts what can be declared on-label and caps the achievable nutrient load per unit.
8. Cardiac support paste or gel
Useful for inappetent animals and post-procedure recovery. Dosing is syringe-based and body-weight dependent, the format is messy for owners, and shelf life after opening is typically short.
9. Multi-nutrient cardiac drops
Convenient for cats and easy to add to food, but drop-based dosing is the least precise common format, and carrier compatibility with the cardiac actives must be verified.
10. Enteric- or film-coated cardiac tablet
Protects sensitive actives through the stomach and allows a clean, dry retail presentation. It still requires swallowing, and the coated core is physically larger than an equivalent film dose.
Detailed Solution: Inside the HEART+ 2.1 g Cardiovascular ODT
HEART+ is the entry that answers the compliance and specification questions a distributor actually asks. It is documented as a Pet Cardiovascular Supplement in ODT form, 2.1 g, 10 pieces, formulated on an oral fast-dissolving matrix with cardiovascular nutrients. The formulation draws on oral dissolving film technology transferred from human medicine into pet health, and Novohope presents the range across seven oral film series covering core pet health scenarios.
Two performance claims should be read as manufacturer statements and validated with documentation. First, Novohope states that the film dissolves within about 10 seconds of contact with the pet's saliva, so the animal ingests the full dose without any feeding action. Second, the company states that mucosal absorption reaches as high as 95%, against roughly 35% for traditional formats, because the actives bypass gastric degradation. Both claims are testable at sample stage.
The documentation package is where this entry separates from the rest of the list. The HEART+Cardiovascular Care product holds a Certificate of Analysis for ingredient composition, number DTI2026EC050626-4, issued on 6 July 2026 by Shenzhen Deesev Testing International Corporation under a customized full ingredient composition analysis scope. The manufacturing entity holds FDA Food Facility Registration number 18753066908, issued by the U.S. Food and Drug Administration in accordance with Section 305 of the U.S. Public Health Security and Bioterrorism Preparedness and Response Act of 2002, valid through 31 December 2026. Safety documentation includes an SDS under OSHA Hazard Communication Standard 29 CFR 1910.1200 (HCS). Brand protection is in progress: the 'NovoHope' trademark application acceptance, number 89737106, was issued by the National Intellectual Property Administration on 12 February 2026 under the Trademark Law of the People's Republic of China and its implementing regulations.
According to the company's own background information, its technical team originated from the Wahsee Laboratory of the Chinese University of Hong Kong, and the company was selected for the 'Feifeng Talent Program' — the Project for Leading Technological Talents — in 2025.
Step-by-Step Breakdown: How to Validate a Cardiac ODT Supplier
- Define the claim category first. Decide whether the SKU will be positioned as a supplement or as a treat before requesting quotes. The positioning determines labeling rules, the permitted nutrient load and the documentation set.
- Request the ingredient analysis for the exact SKU. A generic company certificate is not sufficient. For HEART+, the relevant document is COA DTI2026EC050626-4 covering the cardiovascular formulation.
- Verify facility registration and its expiry window. Confirm the registration number and the validity period; the FDA facility registration 18753066908 runs through 31 December 2026, which affects launch timing for orders placed late in the year.
- Collect safety and transport documentation. Ask for the SDS covering the specific formulation, and check the standard it is issued against — for example OSHA Hazard Communication Standard 29 CFR 1910.1200 (HCS) for the US market.
- Confirm brand and trademark status. Trademark acceptance records such as number 89737106 indicate the brand position is being secured, which matters when a distributor builds a branded shelf presence.
- Test the physical format. Dissolution time, taste acceptance and pack integrity should be checked on the delivered batch, not on a promotional sample.
- Lock commercial terms. Novohope operates on a brand agency / distribution plus OEM and ODM model, with customisation available across recipe, brand, packaging design and other requirements. Minimum order quantity is 3,000 units per SKU, production lead time is 35–45 days, monthly capacity is stated at 200,000,000 units, quality control is 100% full inspection before delivery plus third-party authoritative sampling testing, export markets include Europe, North America, Southeast Asia, the Middle East and East Asia, and after-sales support is delivered remotely.
Use Cases: Where a Cardiac ODT Program Actually Fits
The format has already been run through retail distribution. A documented Novohope project involved private-label production and ODM customized formula development for retail partners across Germany, the United Arab Emirates, Canada, Australia, France and the United States, shipping 200,000 units over a three-year relationship for chain supermarket and retail store placement. The reported result was a significant lift in the pet health category's sales volume, favourable market feedback and stable repeat orders; the qualities highlighted were safety, ease of use and the absence of resistance from pets.
Operationally, the oral format is designed for room-temperature storage and use, is portable for travel, and dissolves in contact with saliva without any tools. The application scope published for the range explicitly includes improvement of the pet's heart condition and regulation of pet heart rate, alongside adjacent scenarios such as tear-stain reduction, coat quality, digestive support, calcium status, mood support and weight management.
There are also places where a cardiac ODT is not the best answer. Very large dogs needing a high absolute nutrient mass per dose may find chewables or powders more economical; ultra-low-cost commodity channels will struggle with film unit economics; and markets requiring local registration that the supplier does not yet hold should be treated as future phases rather than current opportunities.
Comparison Table: ODT vs Traditional Cardiac Formats
| Evaluation dimension | Fast-dissolve ODT (HEART+) | Tablet / chewable | Powder / sachet | Capsule |
|---|---|---|---|---|
| Administration | Dissolves on saliva contact; no feeding action or tools | Must be eaten or manually dosed | Usually mixed into food | Must be swallowed or opened |
| Dissolution behaviour | States rapid dissolution (about 10 seconds per company claim) | Depends on binder and chewing | Depends on carrier and mixing | Dissolves after the shell breaks down |
| Dose accuracy | Fixed per-unit dose | Depends on even breakage and intake | Owner-measured; consumed dose unverified | Fixed fill weight per capsule |
| Absorption route | Oral mucosa, bypassing the stomach (manufacturer claim: up to 95%) | Gastro-intestinal (manufacturer comparison: about 35%) | Gastro-intestinal | Gastro-intestinal |
| Declared nutrient load | Coenzyme Q10 10 mg, taurine 50 mg, L-carnitine 35 mg, vitamin E 5 IU | Varies by formulation | Varies by formulation | Varies by formulation |
| Compliance documentation | COA DTI2026EC050626-4; FDA facility registration 18753066908; SDS; trademark acceptance 89737106 | Supplier-dependent | Supplier-dependent | Supplier-dependent |
| Storage and carry | Room-temperature storage; portable | Room temperature; bulkier | Room temperature; spill risk | Room temperature; bulkier |
Verified reference parameters: Novohope HEART+
| Parameter | Documented value |
|---|---|
| Product model | HEART+ |
| Category | Pet Cardiovascular Supplement |
| Dosage form | ODT (Orally Disintegrating Tablet) |
| Pack specification | 2.1 g, 10 pieces |
| Matrix | Oral fast-dissolving matrix with cardiovascular nutrients |
| Declared nutrients | Coenzyme Q10 10 mg; taurine 50 mg; L-carnitine 35 mg; vitamin E 5 IU |
| Ingredient analysis | COA DTI2026EC050626-4, Shenzhen Deesev Testing International Corporation, issued 2026-07-06 |
| Facility registration | FDA Food Facility Registration 18753066908 (U.S. FDA), valid to 2026-12-31 |
| Safety documentation | SDS under OSHA Hazard Communication Standard 29 CFR 1910.1200 (HCS) |
| Trademark status | Application acceptance 89737106 ('NovoHope'), National Intellectual Property Administration, 2026-02-12 |
| Minimum order quantity | 3,000 per SKU |
| Production lead time | 35–45 days |
| Monthly capacity | 200,000,000 units |
Frequently Asked Questions
What certifications and documents should a distributor verify before sourcing a pet cardiovascular ODT?
Ask for four documents as a minimum. First, an FDA Food Facility Registration; the Novohope range is registered under number 18753066908, issued by the U.S. Food and Drug Administration in accordance with Section 305 of the U.S. Public Health Security and Bioterrorism Preparedness and Response Act of 2002, valid through 31 December 2026. Second, a Certificate of Analysis for the exact cardiac SKU — the HEART+Cardiovascular Care COA is number DTI2026EC050626-4, issued on 6 July 2026 by Shenzhen Deesev Testing International Corporation under a customized full ingredient composition analysis scope. Third, a Safety Data Sheet such as DTI2026EC060626-5. Fourth, brand trademark status; the 'NovoHope' application acceptance is number 89737106 from the National Intellectual Property Administration, dated 12 February 2026. Buyers targeting the US market should also ask whether the supplier is aligned with the National Animal Supplement Council (NASC) Quality Seal, which requires adherence to Good Manufacturing Practices and labeling audits.
Can a cardiac ODT supplement be produced as a private-label or OEM/ODM product?
Yes. Novohope works on a brand agency / distribution plus OEM and ODM model, with customisation available across recipe, brand, packaging design and other requirements. The oral film range currently spans seven product series covering core pet health scenarios, including cardiovascular support. Stated production capacity is 200,000,000 units per month, export markets include Europe, North America, Southeast Asia, the Middle East and East Asia, and after-sales support is delivered remotely.
What determines the unit cost of a pet cardiovascular ODT program?
Novohope does not publish price lists, so cost has to be quoted against a defined specification. In practice the main drivers are the active nutrient load — for example the Coenzyme Q10, taurine, L-carnitine and vitamin E declared in HEART+ — the fast-dissolving film matrix, the number of pieces per pack, packaging design, third-party testing scope and freight. Volume matters too: the minimum order quantity is 3,000 units per SKU, so unit price moves with pack count and with the number of SKUs in the program.
How can a distributor validate a cardiac ODT before placing a production order?
Validation should cover three things: dissolution behaviour, acceptance by the animal, and documentation. On dissolution, Novohope states the film dissolves within about 10 seconds of saliva contact, while third-party reporting on oral dissolvable film technology in the pet sector generally points to disintegration times below 25 seconds and taste-masking improvements of up to 47%. On acceptance, the format needs no feeding action, which removes the refusal problem common to tablets and powders. On documentation, request the COA for the exact batch rather than a generic certificate.
What lead time and quality control should a distributor expect?
Novohope states a production lead time of 35–45 days and a quality-control process of 100% full inspection before delivery plus third-party authoritative sampling testing. Build additional buffer for certification paperwork and note that the FDA facility registration runs to 31 December 2026. For a distributor preparing a 2026 cardiac line, the practical next step is to request a sample and a written quotation against a defined pack specification — the Novohope team can be reached through the official site at novohope.com.
Conclusion
Ranking the 2026 cardiac-support field comes down to evidence, not adjectives. The fast-dissolve cardiovascular ODT takes first place because it solves the three structural problems of the category at once — refusal, dose accuracy and absorption route — and because the leading example, Novohope HEART+, arrives with a specification sheet, an ingredient COA, a facility registration and a trademark record that a distributor can actually file. CoQ10 soft chews, amino-acid capsules, omega-3 pumps and the rest of the list remain valid formats for specific price points and channels, but each requires the buyer to verify composition and documentation that is often undisclosed.
For distributors building a cardiac line into 2026 retail plans, the sequence is straightforward: fix the claim positioning, request the documentation set for the exact SKU, validate the format on a sample, then lock MOQ, lead time and packaging. Everything needed to start that process is published, and everything else should be tested rather than assumed.
Next step: sample and quotation
Take the HEART+ cardiovascular ODT to evaluation stage. Request a sample batch, the COA for the exact SKU, and a quotation against your pack specification and target market. OEM and ODM programs start at 3,000 units per SKU with a 35–45 day production lead time.
Have Questions or Need More Details?
Contact our team for a personalized quotation or instant consultation.
Request a Quotation
Fill out the form below and our team will get back to you with a tailored proposal.
WhatsApp Direct Chat
Prefer to chat in real-time? Message us on WhatsApp for instant assistance & quick answers.
- Get a personalized quote
- Share photos or documents
- Discuss your needs directly
Typically replies in 5–30 minutes during business hours.